Ocugen Q2 2025 Financial Results and Business Update

SEC Filing 8-K (0001104659-25-072992)

Ocugen, Inc. reported its second quarter 2025 financial results and provided a business update. The company announced progress in its clinical trials, including the initiation of dosing in the OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trial for Stargardt disease. Additionally, Ocugen is actively dosing patients in the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa, with a Biologics License Application (BLA) filing targeted for 2026. The company also signed a binding term sheet for exclusive Korean rights to OCU400, which could generate up to $11 million in upfront fees and milestone payments. Ocugen's cash, cash equivalents, and restricted cash totaled $27.3 million as of June 30, 2025, providing a cash runway into the first quarter of 2026. The company reported a net loss of $0.05 per share for the quarter.